The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Current understanding of the biological mechanisms underlying disease progression in MPNs
Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, highlights biological mechanisms underlying disease progression in MPNs, including the progress in research evaluating the effects of JAK2, CALR, MPL, and high-risk mutations. He explains that these biological mechanisms are still not fully understood and emphasizes the need for further research. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
